Abstract
Normal bone homeostasis is the result of a cross-talk between the anabolic axis (osteoblast differentiation) and catabolic axis (osteoclast remodeling). A disruption of this tightly regulated relationship leads to imbalanced bone turnover which ultimately results in diseases of the skeleton. Given that the majority of disease states are characterized by an inadequate renewal of osteoblasts, and the canonical wingless (Wnt) pathway is critical for their differentiation from progenitors, this represents an intriguing target for bone therapy. This mini-review focuses on the different options available for pharmaceutical enhancement of osteogenic differentiation through targeting the various proteins involved in Wnt signaling.
Keywords: Dkk-1, glycogen-synthetase-kinase-3β, mesenchymal stem/progenitor cell, osteogenic differentiation, Wnt-signaling
Current Molecular Pharmacology
Title:Potential of Modulating Wnt Signaling Pathway Toward the Development of Bone Anabolic Agent
Volume: 5
Author(s): Ulf Krause and Carl A. Gregory
Affiliation:
Keywords: Dkk-1, glycogen-synthetase-kinase-3β, mesenchymal stem/progenitor cell, osteogenic differentiation, Wnt-signaling
Abstract: Normal bone homeostasis is the result of a cross-talk between the anabolic axis (osteoblast differentiation) and catabolic axis (osteoclast remodeling). A disruption of this tightly regulated relationship leads to imbalanced bone turnover which ultimately results in diseases of the skeleton. Given that the majority of disease states are characterized by an inadequate renewal of osteoblasts, and the canonical wingless (Wnt) pathway is critical for their differentiation from progenitors, this represents an intriguing target for bone therapy. This mini-review focuses on the different options available for pharmaceutical enhancement of osteogenic differentiation through targeting the various proteins involved in Wnt signaling.
Export Options
About this article
Cite this article as:
Krause Ulf and A. Gregory Carl, Potential of Modulating Wnt Signaling Pathway Toward the Development of Bone Anabolic Agent, Current Molecular Pharmacology 2012; 5 (2) . https://dx.doi.org/10.2174/1874467211205020164
DOI https://dx.doi.org/10.2174/1874467211205020164 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: The RB-Pathway in Cancer (Executive Editor: Erik Knudsen)]
Current Molecular Medicine Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Current Drug Targets Drug Tissue Distribution: Study Methods and Therapeutic Implications
Current Pharmaceutical Design Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry Chemical and Biological Profile of Dual Cdk1 and Cdk2 Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Current Medicinal Chemistry Peripheral Benzodiazepine Receptor (PBR) New Insight in Cell Proliferation and Cell Differentiation Review
Current Clinical Pharmacology Baculovirus Gene Delivery: A Flexible Assay Development Tool
Current Gene Therapy The DREAM of Pain Relief
Current Rheumatology Reviews Pharmacological Intervention at CCR1 and CCR5 as an Approach for Cancer: Help or Hindrance
Current Topics in Medicinal Chemistry Resveratrol: A New Potential Therapeutic Agent for Melanoma?
Current Medicinal Chemistry New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Psoriasin, A Multifunctional Player in Different Diseases
Current Protein & Peptide Science Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry The Role of Mitochondria in Cancer Induction, Progression and Changes in Metabolism
Mini-Reviews in Medicinal Chemistry Genetics of Bladder Malignant Tumors in Childhood
Current Genomics Carbohydrate-Metal Complexes and their Potential as Anticancer Agents
Current Medicinal Chemistry Macroautophagy as a Target of Cancer Therapy
Current Cancer Therapy Reviews Recent Progress in the Development of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Gene Therapy in In Vivo Isolated Perfusion Models
Current Gene Therapy